INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) has announced the addition of Platelet-Rich Plasma (PRP) therapy to its fertility services at the Wisconsin Fertility Institute center. The treatment utilizes the body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response.
The therapy is specifically designed for women facing particular fertility challenges, including those with thin uterine lining, diminished ovarian reserve, and patients seeking alternatives before considering egg donation or surrogacy. Dr. Gretchen Collins, a double board certified OB/GYN and REI at Wisconsin Fertility Institute, notes that while PRP therapy remains experimental in fertility treatment, it has demonstrated success in other medical fields such as orthopedics and wound healing.
Positive
- Introduction of new innovative PRP therapy treatment option
- Minimally invasive approach using patient's own biological resources
- Potential alternative before pursuing more complex options like egg donation or surrogacy
- Treatment addresses multiple fertility challenges including thin uterine lining and diminished ovarian reserve
Negative
- PRP therapy is still considered experimental in fertility treatment
- Clinical effectiveness in fertility applications still being studied
Insights
INVO adds experimental PRP therapy at Wisconsin clinic; potentially broadens treatment options but clinical effectiveness still being studied.
INVO Fertility's introduction of Platelet-Rich Plasma (PRP) therapy at their Wisconsin center represents a calculated expansion into emerging fertility technologies. PRP therapy – which utilizes a patient's own growth factors to potentially stimulate uterine lining development and ovarian function – targets specific fertility challenges including thin endometrial lining and diminished ovarian reserve.
The clinical positioning here is notably measured. Dr. Collins explicitly characterizes PRP as "experimental but promising" in reproductive applications, while acknowledging its established benefits in orthopedics and wound healing. This transparency regarding its investigational status in fertility demonstrates appropriate clinical caution.
From a treatment perspective, PRP occupies a strategic middle ground in the fertility care spectrum – offering an additional option before patients progress to more involved procedures like egg donation or surrogacy. This positions INVO to potentially retain patients who might otherwise seek alternatives elsewhere.
The single-location implementation suggests a deliberate pilot approach rather than a comprehensive rollout. While this limits immediate market impact, it allows for experience-building with the technique before wider deployment.
This addition complements INVO's existing offerings and aligns with growing patient preference for treatments utilizing the body's own resources. However, without established efficacy data specific to fertility outcomes, its clinical and financial impact remains uncertain. The careful framing as an "additional option" rather than a breakthrough appropriately manages expectations while expanding INVO's treatment portfolio.
MIDDLETON, Wis. and SARASOTA, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility market, is excited to announce the addition of Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at its Wisconsin Fertility Institute center. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges, further expanding the center’s commitment to innovative, patient-centered care.
PRP is a cutting-edge treatment that uses your body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response. PRP therapy is particularly beneficial for women facing specific fertility challenges, including patients with a thin uterine lining; women with diminished ovarian reserve; and those looking to boost their chances of conception. The therapy is ideal for patients seeking alternatives before resorting to options like egg donation or surrogacy, offering a minimally invasive approach using the body’s own resources.
“PRP therapy represents another potentially helpful option in fertility care,” said Steve Shum, CEO of INVO Fertility. “By harnessing the body’s natural healing potential, our team at Wisconsin Fertility Institute is offering new possibilities for patients who may have felt their options were limited. We’re thrilled to bring this innovative treatment to the Wisconsin community.”
Dr. Gretchen Collins, at Wisconsin Fertility Institute, added, “As a double board certified OB/GYN and REI, I understand how deeply challenging fertility struggles can be. Platelet-Rich Plasma (PRP) therapy is an experimental but promising option in reproductive medicine. While its use in fertility is still being studied, PRP has shown value in other areas of medicine—such as orthopedics and wound healing—by supporting tissue repair and regeneration. We're hopeful that similar benefits may extend to ovarian and endometrial health, offering new hope to patients with minimal risk.”
Patients interested in exploring PRP therapy are encouraged to schedule a consultation with Wisconsin Fertility Institute’s team of experienced fertility specialists by visiting https://wisconsinfertility.com/ or at 608-824-0075.
About INVO Fertility
We are a healthcare fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
What is PRP therapy at INVO Fertility's Wisconsin Fertility Institute?
Who can benefit from INVO Fertility's PRP therapy treatment?
Is PRP therapy at INVO Fertility (IVF) proven effective for fertility treatment?
How can patients access PRP therapy at Wisconsin Fertility Institute?
What makes INVO Fertility's PRP therapy different from other fertility treatments?
